It drives me nuts when these things say stuff like "doubles your risk" w/o giving the original risk. Risk doubling from 5% to 10% is not in the same universe as risk doubling from .02% to .04%, which I believe is the actual risk in this case.
It's really frustrating because both papers clearly lays out the numbers in natural frequencies: > During 1,915,120 person-years of observation, 218 persons developed NAION. Semaglutide 51 exposure associated with a higher incidence rate (0·228 vs 0·093 per 1000 person-years, p > In this cohort study conducted in Denmark and Norway, use of semaglutide was associated with an increased risk of NAION; the pooled hazard…
> Both Danish studies show that the risk of developing NAION for the individual patient receiving treatment with Ozempic is only 0.2 per thousand per year, which is fortunately significantly lower than in the American study. NAION is a relatively rare condition, and the extra risk is therefore low. The researchers estimate that for every 10,000 people treated in a year, between 1.5 and 2.5 extra cases will be seen.
Sadly it's still relative, and they still leave you the mental maths to work out the natural frequencies.